Passage BIO

General Information
Business:

 

We are a genetic medicines company focused on developing transformative therapies for rare, monogenic CNS disorders with limited or no approved treatment options. Our vision is to become the premier genetic medicines company by developing and ultimately commercializing therapies that dramatically and positively transform the lives of patients suffering from these life-threatening disorders.

Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
Employees: 20
Founded: 2017
Contact Information
Address Two Commerce Square, 2001 Market Street, 28th Floor, Philadelphia, PA, 19103, US
Phone Number (267) 866-0311
Web Address http://www.passagebio.com
View Prospectus: Passage BIO
Financial Information
Market Cap $669.8mil
Revenues $0 mil (last 12 months)
Net Income $-45.6 mil (last 12 months)
IPO Profile
Symbol PASG
Exchange NASDAQ
Shares (millions): 7.4
Price range $16.00 - $18.00
Est. $ Volume $125.8 mil
Manager / Joint Managers J.P. Morgan/ Goldman Sachs/ Cowen
CO-Managers Chardan
Expected To Trade: 2/28/2020
Day: Friday
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change